Table 3.
Pre- and Posttreatment Demographic and Clinical Characteristics of the Patients in Both the Sustained Virological Response (SVR) and Non-SVR Groups
| Characteristic | Pretreatment | Posttreatment | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| SVR (n=67) | Non-SVR (n=33) | p-value | SVR (n=67) | Non-SVR (n=33) | p-value | |
| Gender, no. (%) | 0.84 | - | ||||
| Male | 42 (62.7) | 20 (60.6) | - | - | ||
| Female | 25 (37.3) | 13 (39.4) | - | - | ||
| Age, yr | 44.3±8.2 | 47.1±7.1 | 0.09 | - | - | - |
| ALT, IU/L | 78.9±6.3 | 81.2±7 | 0.11 | 45.9±5.8 | 79.5±13 | <0.001* |
| AST, IU/L | 70.3±9.2 | 72.9±8.6 | 0.19 | 43.2±6.6 | 70±11.9 | <0.001* |
| ALP, IU/L | 98.4±24.2 | 104.6±21 | 0.2 | 67.5±18.4 | 101.6±25.8 | <0.001* |
| GGT, IU/L | 74.3±10.2 | 76.6±9.8 | 0.29 | 47.7±13.7 | 71.2±14.7 | <0.001* |
| Total bilirubin, mg/dL | 1±0.2 | 1.1±0.2 | 0.06 | 0.6±0.2 | 0.9±0.2 | <0.001* |
| Total protein, g/dL | 6.9±0.7 | 6.6±0.6 | 0.06 | 7.3±0.7 | 6.8±0.7 | 0.001† |
| Albumin, g/dL | 3.6±0.2 | 3.5±0.2 | 0.07 | 4±0.2 | 3.7±0.3 | <0.001* |
| HCV RNA levels, IU/mL | 766,942±235,767.8 | 972,670.4±392,823 | 0.002† | 0.0±0.0 | 11,689±5,120 | <0.001* |
Data are presented as mean±SD unless otherwise indicated.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyltransferase; HCV, hepatitis C virus.
*
Indicates a highly statistically significant difference;
†
Indicates a very statistically significant difference.